Kalaris Therapeutics Inc
Research Kalaris Therapeutics Inc (KLRS) on Bullrun: market cap USD 53.80M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKLRS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 53.80M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 11.52M
- Free cash flow-USD 11.05M
Valuation Snapshot
latest market cap is USD 53.80M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 43.43M | -USD 38.57M | n/a | -2.85 | USD 98.05M | USD 1.45M | USD 78.81M |
| FY2024 | USD 0 | -USD 69.17M | -USD 20.67M | n/a | -51.77 | USD 1.64M | USD 19.54M | -USD 96.62M |
| FY2023 | USD 0 | -USD 190.42M | -USD 14.13M | n/a | -42.09 | USD 90.12M | n/a | -USD 45.02M |
| FY2022 | USD 0 | -USD 168.71M | -USD 9.78M | n/a | -2.2 | USD 106.09M | USD 3.25M | USD 224.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 53.80M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 193.30M | n/a | n/a | n/a |
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kalaris Therapeutics Inc's market cap?
Kalaris Therapeutics Inc's market capitalization is USD 53.80M.
What does Kalaris Therapeutics Inc do?
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.